Disruptive technologies for hemodialysis: medium and high cutoff membranes. Is the future now?
Thiago ReisSiddiq AnwarFrancisco de Assis da Rocha NevesClaudio RoncoPublished in: Jornal brasileiro de nefrologia : 'orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia (2021)
In the past decade, a new class of hemodialysis (HD) membranes (high retention onset class) became available for clinical use. The high cutoff (HCO) and the medium cutoff (MCO) membranes have wider pores and more uniformity in pore size, allowing an increased clearance of uremic toxins. Owing to the mechanism of backfiltration/internal filtration, middle molecules are dragged by the convective forces, and no substitution solution is needed. The HCO dialyzer is applied in septic patients with acute kidney injury requiring continuous kidney replacement therapy. The immune response is modulated thanks to the removal of inflammatory mediators. Another current application for the HCO dialyzer is in hematology, for patients on HD secondary to myeloma-kidney, since free light chains are more efficiently removed with the HCO membrane, reducing their deleterious effect on the renal tubules. In its turn, the MCO dialyzer is used for maintenance HD patients. A myriad of clinical trials published in the last three years consistently demonstrates the ability of this membrane to remove uremic toxins more efficiently than the high-flux membrane, an evolutionary disruption in the HD standard of care. Safety concerns regarding albumin loss as well as blood contamination from pyrogens in the dialysate have been overcome. In this update article, we explore the rise of new dialysis membranes in the light of the scientific evidence that supports their use in clinical practice.
Keyphrases
- toll like receptor
- end stage renal disease
- immune response
- peritoneal dialysis
- chronic kidney disease
- acute kidney injury
- newly diagnosed
- clinical trial
- replacement therapy
- clinical practice
- healthcare
- palliative care
- cardiac surgery
- randomized controlled trial
- smoking cessation
- patient reported outcomes
- dna methylation
- dendritic cells
- pain management
- chronic pain
- current status
- heavy metals
- human health
- open label
- single molecule
- phase ii
- study protocol
- health risk
- double blind